Ophthalmology News

Lumenis to Present Interim Safety and Efficacy Results of IPL with OPT™ for Treating Dry Eye at Major Ophthalmology Meeting

May 5, 2016 - Yokneam, Israel 

Lumenis, Ltd., the world’s largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, will present interim results of a multicenter prospective clinical trial designed to study the safety and efficacy of Optimal Pulse Technology (OPTTM), the next generation of Intense Pulse Light (IPL) technology, for treating Dry Eye Disease (DED). Data from the trial, being led by Steven J. Dell, MD, of Dell Laser Consultants in Austin, Texas, will be presented at a conference of anterior segment ophthalmologists being held May 6-10 in New Orleans, LA. 

PB-2005801 REV A

Lumenis Receives US FDA and Japanese MHLW Clearance for Array™ LaserLink™ Pattern Scanning Device for Multi-spot Retinal Laser Treatment

The Next Generation in Retina Laser Treatment Designed to Allow Significantly Faster and Less Painful Procedures

November 14, 2013 - San Jose, CA

Lumenis Ltd., the world's largest medical laser company for ophthalmic, surgical and aesthetic applications, today announced that the company has received US FDA and Japanese MHLW clearance for its Array™ LaserLink™ pattern scanning device for multi-spot laser photocoagulation.

PB-1004986 Ver.A

New Study by Dr. Tony Realini Demonstrates Lumenis SLT as a Powerful Tool for Reducing Glaucoma-related Blindness in the Developing World

Lumenis Supports Glaucoma Research and Treatment with Selective Laser Trabeculoplasty of Underserved Patients in St. Lucia

June 11, 2013 - San Jose, CA

Lumenis Ltd. Announced today that the company is pledging its support to the work of Tony Realini, MD, MPH, Associate Professor of Ophthalmology, West Virginia University, in improving standards of care for glaucoma patients in underserved populations. Dr. Realini is the author of a recent study demonstrating the benefits of selective laser trabeculoplasty (SLT) for the treatment of primary open-angle glaucoma in an African- ancestry population in St. Lucia. 

PB-1004987 Ver.A

Lumenis® Supports Prestigious Moorfields Eye Hospital in Seminal Glaucoma Study using Lumenis’ Selective Laser Trabeculoplasty (SLT) Technology

Partnering to establish Lumenis’ SLT therapy as the new gold standard for open-angle glaucoma care

May 7, 2013 - San Jose, CA, USA Lumenis Ltd., the world's largest medical laser company for ophthalmic, aesthetic, and surgical applications, and the pioneer of Selective Laser Trabeculoplasty (SLT) technology, announces its support of the Moorfields Eye Hospital in London, UK, to run a seminal glaucoma study using Lumenis’ Selecta® Duet™ SLT Laser system.  The laser in glaucoma and ocular hypertension (LIGHT) study will compare quality of life after glaucoma laser treatment versus eye drop therapy.

PB-1004988 Ver.A

Lumenis® and Renowned Wills Eye Institute Collaborate to Advance Glaucoma Research and Expand Care to Philadelphia’s Most Underserved Populations

February 26, 2013 - San Jose, California.

San Jose, California, February 26, 2013 --  Lumenis Ltd., the world's largest medical laser company for ophthalmic, aesthetic, and surgical applications, and the pioneer of SLT technology, announced a collaboration with the  Wills Eye Institute, Glaucoma Research Center, in Philadelphia to provide access  to glaucoma treatment using  the Selecta® Duet™ SLT Laser system to Philadelphia’s underserved populations.   The Wills Eye Institute will bring the gold standard in glaucoma Laser care to patients around the city to improve eye care for individuals who suffer from this debilitating condition via a mobile unit and will collect epidemiological data with the goal of analyzing the impact of early treatment on disease progression.

PB-1004989 Ver.A